High titre neutralising antibodies to influenza after oral tablet immunisation: A phase 1, randomised, placebo-controlled trial

The Lancet Infectious Diseases

Volumn 15, Issue 9, 2015, Pages 1041-1048

  Liebowitz, David ^a   Lindbloom, Jonathan D ^a   Brandl, Jennifer R ^a   Garg, Shaily J ^a   Tucker, Sean N ^a  

^a Vaxart Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; DOUBLE STRANDED RNA; HEMAGGLUTININ; INFLUENZA VACCINE; NEUTRALIZING ANTIBODY; PLACEBO; TABLET; VIRUS ANTIBODY;

ABDOMINAL PAIN; ADULT; ANOREXIA; ANTIBODY SECRETING CELL; ARTICLE; ASSAY; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG INDUCED HEADACHE; DRUG SAFETY; FEMALE; FEVER; HEMAGGLUTINATION INHIBITION; HUMAN; HUMAN EXPERIMENT; IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; INFLUENZA; MALAISE; MALE; NAUSEA; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; VOMITING; BLOOD; CLINICAL TRIAL; HEMAGGLUTINATION INHIBITION TEST; IMMUNOLOGY; INFLUENZA A VIRUS (H1N1); MIDDLE AGED; ORAL DRUG ADMINISTRATION; SERODIAGNOSIS; TABLET; YOUNG ADULT;

ADMINISTRATION, ORAL; ADULT; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DIARRHEA; DOUBLE-BLIND METHOD; FEMALE; FEVER; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; NEUTRALIZATION TESTS; TABLETS; YOUNG ADULT;

EID: 84939780865     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(15)00266-2     Document Type: Article

References (17)

1. National strategy for pandemic influenza: implementation plan one year summary Homeland Security Council, (accessed Sept 17, 2014). http://www.flu.gov/planning-preparedness/federal/.
2. Peters W, Brandl JR, Lindbloom JD, et al. Oral administration of an adenovirus vector encoding both an avian influenza A hemagglutinin and a TLR3 ligand induces antigen specific granzyme B and IFN-gamma T cell responses in humans. Vaccine 2013, 31:1752-1758.
3. Scallan CD, Tingley DW, Lindbloom JD, Toomey JS, Tucker SN An adenoviral-based vaccine with a dsRNA adjuvant protects against H5N1 avian influenza in oral delivery models in mice and ferrets. Clin Vaccine Immunol 2013, 20:85-94.
4. Guidance for industry: toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials FDA, (accessed March 17, 2017). http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm074775.htm.
5. Greenberg ME, Lai MH, Hartel GF, et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med 2009, 361:2405-2413.
6. Note for guidance on harmonisation of requirements for influenza vaccines EMEA, (accessed Sept 17, 2014). http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000407.jsp&mid=WC0b01ac058002958b.
7. Reber A, Katz J Immunological assessment of influenza vaccines and immune correlates of protecton. Exp Rev Vaccines 2013, 12:519-536.
8. Hsieh MM, Everhart JE, Byrd-Holt DD, Tisdale JF, Rodgers GP Prevalence of neutropenia in the U.S. population: age, sex, smoking status, and ethnic differences. Ann Intern Med 2007, 146:486-492.
9. Faix DJ, Hawksworth AW, Myers CA, et al. Decreased serologic response in vaccinated military recruits during 2011 correspond to genetic drift in concurrent circulating pandemic A/H1N1 viruses. PloS One 2012, 7:e34581.
10. Gordon DL, Sajkov D, Woodman RJ, et al. Randomized clinical trial of immunogenicity and safety of a recombinant H1N1/2009 pandemic influenza vaccine containing Advax polysaccharide adjuvant. Vaccine 2012, 30:5407-5416.
11. Crum-Cianflone NF, Iverson E, Defang G, et al. Durability of antibody responses after receipt of the monovalent 2009 pandemic influenza A (H1N1) vaccine among HIV-infected and HIV-uninfected adults. Vaccine 2011, 29:3183-3191.
12. Leroux-Roels I, Roman F, Forgus S, et al. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study. Vaccine 2010, 28:849-857.
13. Ledgerwood JE, Costner P, Desai N, et al. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine 2010, 29:304-313.
14. Xiang ZQ, Gao GP, Reyes-Sandoval A, Li Y, Wilson JM, Ertl HC Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier. J Virol 2003, 77:10780-10789.
15. O'Brien KL, Liu J, King SL, et al. Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans. Nat Med 2009, 15:873-875.
16. Gurwith M, Lock M, Taylor EM, et al. Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study. Lancet Infect Dis 2013, 13:238-250.
17. Saha S, Dean B, Teutsch S, et al. Efficiency of points of dispensing for influenza A(H1N1)pdm09 vaccination, Los Angeles County, California, USA, 2009. Emerg Infect Dis 2014, 20:590-595.